Stemline Therapeutics (STML) Received its Third Buy in a Row

By Ryan Adsit

After H.C. Wainwright and Wedbush gave Stemline Therapeutics (NASDAQ: STML) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics today. The company’s shares closed last Monday at $10.86.

According to TipRanks.com, Peaker is a 1-star analyst with an average return of -1.6% and a 40.7% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Pacira Pharmaceuticals, and Emergent Biosolutions.

Stemline Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $26.00, implying a 145.5% upside from current levels. In a report issued on November 11, Wedbush also maintained a Buy rating on the stock with a $17.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.22 and a one-year low of $7.82. Currently, Stemline Therapeutics has an average volume of 651.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.